CANCER-ASSOCIATED IMMUNOSUPPRESSION INHIBITOR

The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragmen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DONNADIEU Emmanuel, LAHMAR Mehdi, DEGOVE Stéphane, BOUGHERARA Houcine, PROST Jean-françois, BARRET Jean-marc
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound. La presente invención se refiere a un compuesto portador de fragmento Fc modificado mediante glicoingeniería para su uso como un inhibidor de inmunosupresión en el tratamiento de una inmunosupresión asociada a cáncer. La invención se refiere además a una composición farmacéutica que comprende por lo menos este compuesto portador de fragmento Fc modificado mediante glicoingeniería.